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Sleeplessness, a universal condi-
tion with diverse causes, may be in-
creasingly diagnosed and treated (or
medicalized) as insomnia. We exam-
ined the trend in sleeplessness com-
plaints, diagnoses, and prescriptions
of sedative hypnotics in physician
office visits from 1993 to 2007. Con-
sistent with the medicalization hy-
pothesis, sleeplessness complaints
and insomnia diagnoses increased
over time and were far outpaced by
prescriptions for sedative hypnotics.
Insomnia may be a public health
concern, but potential overtreatment
with marginally effective, expensive
medications with nontrivial side ef-
fectsraisesdefinitepopulationhealth
concerns. (Am J Public Health.
2011;101:1429–1433. doi:10.2105/
AJPH.2010.300014)
The occasional inability to sleep, or sleepless-
ness, is part of the universal human experience
and has been recorded by ancient and modern
authors.1--4 Recently, however, sleeplessness has
been characterized as an epidemic5 and an unmet
public health problem.6 Insomnia diagnoses in
the United States, which appear to be increasing,
are associated with poor health outcomes and
may cost $100 billion annually in health services,
accidents, and lost productivity.7--9
It is unclear, however, if the United States is
facing a true insomnia epidemic or a surplus of
diagnoses and drug prescriptions.10 Sleep pat-
terns are influenced by changing cultural norms,
shifting demographics (adults ‡65 years are
more likely to be sleepless11), and increased use of
technology.6,12,13 Awareness raised by public
health and pharmaceutical agencies may facili-
tate new diagnoses.14,15 Medicalization may also
contribute to the increased perception, diagnosis,
and treatment of sleeplessness as the medical
condition insomnia.3
Medicalization is the process by which for-
merly normal biological processes or behaviors
come to be described, accepted, or treated as
medical problems.16 The process is value neu-
tral, but outcomes affect individual and public
health.16 Medicalization may raise awareness
about and improve access to beneficial medical
treatments for previously underrecognized dis-
orders.17 Conversely, it may reframe and trans-
form ideas of physical and emotional normalcy
prompting the overuse of potentially harmful
drugs or surgery.18,19 Excessive or inappropriate
use of medical solutions to treat life problems
may negatively affect public health.10,17--19
We explored the idea that the US epidemic
of insomnia may be, in part, facilitated by
medicalization. Explorations of medicalization
are typically qualitative and focus on the
conceptual nature of the disorder.17 Sleep is no
exception.20--23 Our research is the first to our
knowledge to focus on the measurable outcomes
of the patient---physician interaction surrounding
sleeplessness and the public health implications.
Using nationally representative office visit
data we measured trends over time in (1)
complaints of sleeplessness, (2) diagnoses of
insomnia, and (3) prescriptions of sedative
hypnotics. Medicalization theory predicts an
increasing incidence of insomnia diagnoses
and treatments over time that outpace sleep-
lessness complaints, particularly among
younger adults.
METHODS
We used the National Ambulatory Medical
Care Survey (NAMCS), an annual population-
based, nationally representative survey of US
office-based physician visits conducted by the
National Center for Health Statistics (NCHS).
The NAMCS provides information on private-
pay and public-sector patients using a multi-
stage geographically clustered probability
sample of approximately 3000 randomly
chosen physicians per year.24
The unit of analysis was the office visit. To
maintain International Classification of Diseases,
Ninth Revision (ICD-9)25 code consistency for
insomnia diagnosis and capture 1 year of data
before the introduction of zolpidem, the first
of the nonbenzodiazepine sedative hypnotics
(NBSHs), we examined data from 1993 to 2007
for adults aged 18 years and older.
Key variables included the following:
d Sleeplessness as reason for office visit (com-
plaints of ‘‘sleeplessness,’’ ‘‘can’t sleep,’’
‘‘trouble falling asleep’’ [NCHS code 1135.1]);
d Diagnoses of insomnia (ICD-9 diagnosis
codes 78052, 78050, 3074, 78059,
30742, 3074, 30748, 78056, 78055,
30741, 30742, 30749, 32700, and
32709);
d Prescription of benzodiazepines (estazolam,
flurazepam, quazepam, temazepam, and tria-
zolam) or NBSHs (zolpidem, zaleplon, eszopi-
clone, and ramelteon) indicated for insomnia.
We calculated means and 95% confidence
intervals using SVY commands in Stata version
10 (StataCorp LP, College Station, TX), which
adjust for the complex weighted design of
NAMCS. We calculated rates per 10000 visits
for each type of event (complaint, diagnosis,
and prescription) and age group (18---44, 45---
64, and ‡65 years) and regressed on year
using a bivariate linear model. The regression
coefficients (slopes) represent the average an-
nual increase in each type of event over the 15-
year observation period. Because of small cell
sizes, we combined data years into 5 blocks
of 3-year increments when calculating out-
comes by age groups.
RESULTS
Table 1 reveals that approximately 2.7 mil-
lion adult office visits involved complaints of
sleeplessness in 1993. By 2007, this figure had
more than doubled to 5.7 million. During the
same period, insomnia diagnoses increased
more than 7-fold, from about 840000 to 6.1
million. Approximately 2.5 million office visits
in 1993 resulted in a prescription for a ben-
zodiazepine, compared with 3.7 million in
2007. Prescriptions for NBSHs increased
about 30-fold from 1994 (540000 prescrip-
tions) to 2007 (16.2 million).
We observed linear slopes over time for
rates of sleeplessness complaints (b=203712),
insomnia diagnoses (b=301178), and pre-
scriptions for benzodiazepines (b=113624)
and NBSHs (b=1029827). Given the large
sample size, all slopes were positive and
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statistically significant. However, the NBSH
trajectory far outpaced other outcomes.
Figure 1, which illustrates Table 1 data,
shows the actual time trends in the 4 variables.
Complaints of sleeplessness exceeded diagnosis
rates from 1993 through 2005; by 2006,
however, these lines had merged. Over time,
NBSH prescriptions far outpaced both com-
plaints of sleeplessness and diagnoses of insom-
nia. By 2007, more than 1.6% of all office visits
in the United States were generating these pre-
scriptions. The temporal linear correlations in
order by strength (0.94---0.77) were diagnoses,
NBSH prescriptions, complaints, and benzodi-
azepines. All were strong, confirming the linear
trajectories of the variables over time.
By the year 2000, adults aged 65 years and
older were less likely than were those aged
18 to 44 years or 45 to 64 years to list
sleeplessness as the reason for an office visit or
to receive an insomnia diagnosis. As seen in
Table 2, from1996 to1998 onward those aged
65 years and older were less likely to receive
an NBSH prescription than were those aged 45
to 64 years. Compared with other age groups,
adults aged 65 years and older were most
likely to receive a benzodiazepine prescription
in all years, but, as indicated by low temporal
correlations and small negative slopes, their
sleeplessness complaints and benzodiazepine
prescriptions did not increase steadily over
time. The steepest slopes are for the NBSH
prescriptions across all age groups.
DISCUSSION
Analysis of NAMCS data over a 15-year
period revealed a striking disparity between
rates of sleeplessness complaints and insomnia
diagnoses compared with the rapid increase in
NBSHs prescribed. NBSH prescriptions grew
21 times more rapidly than did sleeplessness
complaints and 5 times more rapidly than did
insomnia diagnoses, suggesting that life prob-
lems are being treated with medical solutions,
without benefit of formal complaint or diag-
nosis. Conversely, tandem increases in diagno-
sis and treatment––or significant increases in
diagnosis alone––would suggest greater preva-
lence of a discrete disease state.
Age trends were also suggestive of medical-
ization. Although middle-aged (those aged 45---
64 years) and sometimes younger adults (those
aged 18---44 years) lack the changing sleep
architecture and increased comorbidities of
older adults,26 they still outpaced those aged 65
years and older on all sleeplessness-related
measures, excluding benzodiazepine prescrip-
tion. Increased sleeplessness among young and
middle-aged adults may be attributable to non-
biological issues, including stress, multiple social
roles, increased use of technology, or targeted
marketing of sleep-inducing drugs.3,6,15
Also noteworthy is the convergence of the
numbers of complaints and diagnoses in
2006 and 2007. Previously, sleeplessness
complaints were more likely to result in a di-
agnosis of mental illness.27 Greater awareness
of correlations between insomnia, health, and
quality of life may result in the topic of sleep
being introduced in unrelated office visits,
prompting diagnoses.28,29 Medicalization may
TABLE 1—National Estimates of Sleeplessness-Related Complaints, Diagnoses, and Prescriptions for Benzodiazepine and





Estimated No. (95% CI),
Insomnia Diagnoses,
Estimated No. (95% CI),
BDZ Prescriptions,
Estimated No. (95% CI),
NBSH Prescriptions,
Estimated No. (95% CI),
1993 35 978 (717.2) 2.7 (1.9, 3.5) 0.8 (0.4, 1.3) 2.5 (1.7, 3.4) NAa
1994 33 598 (681.5) 2.9 (1.9, 3.9) 1.1 (0.7, 1.6) 2.0 (1.4, 2.6) 0.54 (0.3, 0.8)
1995 36 875 (697.1) 2.8 (2.0, 3.7) 1.4 (0.9, 1.9) 1.9 (1.3, 2.4) 1.1 (0.8, 1.5)
1996 29 805 (734.5) 3.2 (2.4, 4.0) 1.6 (1.0, 2.2) 1.9 (0.8, 3.0) 1.6 (1.0, 2.3)
1997 24 715 (787.4) 3.8 (2.7, 4.8) 2.3 (1.2, 3.4) 1.8 (1.2, 2.3) 2.1 (1.4, 2.7)
1998 23 339 (829.3) 3.7 (2.6, 4.8) 2.8 (1.5, 4.1) 2.2 (1.4, 3.0) 2.1 (1.4, 2.9)
1999 20 760 (756.7) 5.0 (3.2, 6.8) 2.3 (1.6, 3.1) 2.3 (1.4, 3.2) 2.4 (1.7, 3.2)
2000 27 369 (823.5) 5.1 (3.8, 6.4) 3.1 (2.0, 4.1) 2.2 (1.1, 3.2) 3.3 (2.2, 4.5)
2001 24 281 (880.5) 4.5 (3.1, 5.8) 2.7 (1.8, 3.7) 3.0 (2.0, 4.1) 4.8 (3.5, 6.1)
2002 28 738 (890.0) 4.4 (3.2, 5.6) 3.1 (2.0, 4.3) 1.9 (1.2, 2.6) 4.4 (3.3, 5.4)
2003 25 288 (906.0) 5.0 (3.7, 6.4) 3.6 (2.4, 4.7) 2.4 (1.5, 3.4) 6.3 (5.0, 7.6)
2004 25 286 (910.9) 5.0 (3.7, 6.4) 3.2 (1.9, 4.5) 3.0 (2.1, 4.0) 8.4 (6.3, 10.6)
2005 25 665 (963.6) 5.9 (4.4, 7.5) 4.2 (2.8, 5.5) 3.4 (2.2, 4.6) 12.3 (9.9, 14.7)
2006 29 392 (902.0) 4.4 (3.3, 5.5) 5.2 (3.7, 6.6) 3.5 (2.5, 4.5) 12.6 (10.5, 14.8)
2007 32 778 (994.3) 5.7 (4.4, 7.1) 6.1 (4.8, 7.5) 3.7 (2.6, 4.8) 16.2 (13.7, 18.6)
Model statisticsb
Slope, b 203 712 301 178 113 624 1 029 827
Correlation, r 0.87 0.94 0.77 0.93
Note. BDZ = benzodiazepine; NBSH = nonbenzodiazepine sedative hypnotic. All measures are in millions.
aNBSHs were not separately coded in the survey until 1994.
bFor model statistics, b is the slope from bivariate regression of variable on year; r is the temporal correlation of variable with year.
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also be a factor; instead of viewing insomnia as
a symptom of another illness (e.g., depression or
arthritis), it may be viewed as a discrete medical
problem with a pharmacological solution.
Although efficacious treatment of sleep-
lessness positively affects other facets of well-
being,27,28 underlying causes and mode of
therapy are important considerations. NBSHs
are relatively expensive but may be less
addictive than are benzodiazepines.30,31
However, NBSHs increase sleep time by less than
12 minutes on average,32,33 and side effects
include sleep driving, sleep eating, sleep walking,
and short-term amnesia.34,35 NBSHs may be
particularly risky for patients who take multiple
medications, have histories of drug abuse or
mental illness, or are older and at risk for
falls.36,37
Proven nondrug treatments exist; a review
of 48 clinical trials found that almost 80%
of insomnia patients benefited from behav-
ioral therapies for at least 6 months after
treatment completion without known side
effects.38 Sleep hygiene practices (e.g., con-
trolling diet, exercise, and substance use)
and environmental modifications (e.g., light,
temperature, noise) can counteract sleep de-
terrents such as artificial light and 24-hour
Internet access.39 Preventing occupational
stress and implementing job sharing, flexible
hours, and sleep hygiene school curricula,
could reduce the societal burden of sleep-
lessness.6
Despite these facts, prescription sleep aids
remain the treatment of choice for most physi-
cians.40 Physicians’ choices, however, may be
influenced by market pressures, time constraints,
direct-to-consumer advertising, and increased
consumerism among patients.41,42 With greater
awareness and training, clinicians might utilize
more nondrug treatments.43,44 Patients, in turn,
require more information about the deleterious
health effects of long-term sleep loss and the
benefits of behavioral therapies.
Although this study goes beyond previous
work on the medicalization of sleep by using
quantitative indicators to track the outcomes
of the patient---physician interaction and high-
lighting related public health risks, it has several
FIGURE 1—Sleeplessness-related trends of complaint, insomnia diagnosis, benzodiazepine
(BDZ) and nonbenzodiazepine sedative hypnotic (NBSH) prescription as a result of physician
office visits: United States, 1993–2007.
TABLE 2—National Estimates of Sleeplessness-Related Complaints, Diagnoses, and Prescriptions for Benzodiazepine and
Nonbenzodiazepine Sedative Hypnotics as a Result of Physician Office Visits, by Age Group: United States, 1993–2007
Sleeplessness as Reason
for Office Visit, Complaints
Per 10 000 Visits
Insomnia Diagnoses,
Per 10 000 Visits
BDZ Prescriptions,
Per 10 000 Visits
NBSH Prescriptions,
Per 10 000 Visits
Years 18–44 Years 45–64 Years ‡ 65 Years 18–44 Years 45–64 Years ‡ 65 Years 18–44 Years 45–64 Years ‡ 65 Years 18–44 Years 45–64 Years ‡ 65 Years
1993–1995 48.3 55.5 51.7 16.1 25.6 21.9 21.9 34.1 63.6 11.9 17.8 18.1
1996–1998 47.9 67.1 59.9 30.1 37.1 44.0 13.7 37.1 49.3 17.8 42.4 37.0
1999–2001 79.8 71.5 67.6 39.2 44.1 38.7 32.2 36.5 45.1 37.8 79.1 43.5
2002–2004 69.5 85.1 40.8 47.7 57.6 29.2 27.3 32.7 42.3 60.0 110.0 91.9
2005–2007 69.0 81.4 57.1 73.1 71.6 53.0 28.4 46.1 63.9 143.5 228.3 159.0
Model statisticsa
Slope, b 2.10 2.33 –0.28 4.40 3.75 1.58 0.93 0.68 –0.16 10.63 16.95 11.69
Correlation, r 0.70 0.93 –0.13 0.98 0.99 0.61 0.60 0.60 –0.07 0.91 0.95 0.95
Note. BDZ = benzodiazepine; NBSH = nonbenzodiazepine sedative hypnotic.
aFor model statistics, b is the slope from bivariate regression of variable on year-range midpoint.; r is the temporal correlation of variable with year-range midpoint. Ranges are 3 years except for the
first year range for NBSH which is 2 years (1994-1995), because NBSH was not coded in 1993.
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noteworthy limitations. NAMCS was neither
intended nor designed to capture or measure the
medicalization process and may underrepresent
lower-income groups who use emergency ser-
vices for primary health care. Because the unit of
analysis is the office visit, results are suggestive
of, but not equivalent to, patient outcomes.
Finally, NAMCS is cross-sectional, so data may
be capturing the same patients across or within
years. However, the 1-week data collection
period is unlikely to include repeat visitors.
Sleeplessness may very well be a public
health problem, but its medicalization as in-
somnia––a diagnostic entity with predomi-
nantly pharmacological solutions––may en-
courage overuse of expensive, potentially
harmful drugs while deflecting attention from
effective public health approaches. j
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Childhood obesity is a public
health concern with significant
health and economic impacts. We
conducted a prospective experi-
mental study in 4 classrooms in
central Texas to determine the ef-
fect of desks that encourage stand-
ing rather than sitting on caloric
expenditure in children. Students
were monitored with calorie expen-
diture–measuring arm-bands worn
for 10 days in the fall and spring.
The treatment group experienced
significant increases in calorie ex-
penditure over the control group,
a finding that has implications for
policy and practice. (Am J Public
Health. 2011;101:1433–1436. doi:10.
2105/AJPH.2010.300072)
A 2010 report released by the Trust for
America’s Health and the Robert Wood
Johnson Foundation entitled F as in Fat: How
Obesity Threatens America’s Future, 2010 states
that the percentage of overweight and obese
children is at or above 30% in 30 states.1 The
probability of obese children becoming obese
adults is significantly higher than is the proba-
bility among their nonobese counterparts.2,3
Obese children who grow into obese adults also
have more severe health risks than do individ-
uals with adult-onset obesity, including potential
for a shorter lifespan.4,5
School-based physical activity programs and
environmental changes have proven helpful
in increasing health-enhancing physical activi-
ties for children.6-9 However, these activities
typically concentrate on small portions of
a child’s day and miss the opportunity to increase
health-enhancing physical activities through-
out the entire school day, particularly during
instructional time. The pilot study described
in this brief targeted childhood obesity by
increasing passive calorie expenditure in the
classroom. Classroom environments were
modified to increase standing (rather than
sitting) by replacing students’ and teachers’
traditional seated desks with standing height
desks specifically manufactured for this study
(Artco-Bell, Temple, TX); standing height
stools were also provided to allow students to
sit at their discretion. This concept biased the
classroom environment toward standing, en-
couraging healthy movements, and increased
energy expenditure.
METHODS
The intervention was pilot tested during the
2009 to 2010 school year in 4 first-grade
classrooms in an ethnically diverse elementary
school in central Texas; the treatment and
control classrooms were randomly selected.
All of the desks in the 2 treatment classrooms
were converted to stand---sit workstations with
stools, whereas the control classrooms re-
mained unaltered for the entire school year.
Students were told about the desks during the
consent---assent process, and their teachers
reinforced that they could stand or sit at
their discretion. In addition to calorie expen-
diture, our study investigated children’s
standing activity after giving them no specific
instruction that they must stand or sit for any
portion of their day. By the12th week of school
after the treatment, students had acclimated
to their desks; 70% of the students were not
using stools at all, standing 100% of the time
at their primary homeroom workstation, and
the other 30% were standing, on average,
approximately 75% of the time. Differences
in energy expenditure for the most frequent
users compared with the least frequent
users of the standing position were not mea-
sured because the mean time standing for
treatment classes was 91% of homeroom time.
Eighty students (20 each in 4 classrooms)
were contacted for potential inclusion in the
study. Parental consent and child assent were
obtained at the beginning of the school year for
71 participants (58 completed the study by
recording complete data for both fall and
spring data collections––31 from the treatment
group and 27 from the control group). Every
student in the treatment classrooms received
the stand---sit desk; consent was solely for
participation in the data collection activities.
Those that did not consent were children
whose parents who did not attend parent night
and were unable to be reached in the 2 weeks
afterward.
Data collected on each student included
gender; age; initial and final height, weight,
and body mass index (weight in kg divided by
height in m2); body fat percentage; and
calorie expenditure measured by the Body-
Bugg armband (Apex Fitness, Westlake Vil-
lage, CA) worn on the upper left arm during
the course of 5 consecutive school days at
4 intervals during the school year. The
BodyBugg armband device is self-calibrating;
takes frequent measurements, which reduces
wear time needed to collect data; reports
actual wear time of the device; can distin-
guish between different activities and their
intensities; and, unlike an accelerometer-only
device, does not require movement to ac-
quire data on energy expenditure. This type
of armband has been used in studies on
children and adults; early validation studies
on children resulted in modifications of the
algorithm in the software to improve accu-
racy and validity.10--17 The current algorithm,
adjusted on the basis of findings of 2007 and
2008 studies, incorporates height, weight,
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